• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Excopri Approval Change Ono Pharmaceutical's (TSE:4528) Narrative

    Simply Wall St·09/26/2026 10:26:38
    Listen to the news
    • Ono Pharmaceutical recently gained domestic manufacturing and marketing approval in Japan for its antiepileptic Excopri tablets and disclosed a new drug discovery collaboration with Aitia focused on expanding its oncology and specialty medicine portfolio.
    • These developments highlight Ono Pharmaceutical's effort to broaden its revenue base beyond existing oncology products by adding a new neurology therapy and an external research partner to its pipeline.
    • This article examines how Ono Pharmaceutical's investment narrative is influenced by the Excopri approval and related pipeline expansion.

    Scan for more healthcare stocks that could be setting up for similar portfolio shifts by reviewing our handpicked 10 healthcare AI stocks alongside Ono Pharmaceutical.

    What Is Ono Pharmaceutical's Investment Narrative?

    To own Ono Pharmaceutical, you need to believe the oncology and specialty pipeline can offset pressure on the existing portfolio while management keeps execution tight. Recent data shows revenue and net income both declined slightly year on year, and analysts expect both revenue and earnings to contract over the next three years. Against that backdrop, the Excopri approval and the Aitia tie up look more like incremental help to the story than near term game changers, at least until they scale commercially.

    Near term, the appeal is a mix of a 3.28% dividend yield, high quality earnings, and a P/E of 15.1x that screens below some peers and a DCF based fair value estimate. The flip side is a business that relies on higher risk external borrowing, carries low current and forecast return on equity and needs pipeline execution to justify the recent 13.9% price move in the stock. For a shareholder, the question is whether Ono Pharmaceutical can turn a strong one year earnings jump into something more durable.

    Even so, there is a less obvious risk sitting in the background that only really shows up once you look closely at ...

    There's only one way to know the right time to buy, sell or hold Ono Pharmaceutical. Head to Simply Wall St's company report for the latest analysis of Ono Pharmaceutical's Fair Value.

    TSE:4528 1-Year Stock Price Chart
    TSE:4528 1-Year Stock Price Chart

    Exploring Other Perspectives

    Two fair value views from the Simply Wall St Community cluster between ¥2,508 and ¥3,469, which already gives you a wide bracket for Ono Pharmaceutical. Those estimates were set before the 13.9% share price jump and fresh Excopri and Aitia news, so both re-rating risk and opportunity are now firmly on the radar.

    Explore another Ono Pharmaceutical fair value estimate, including one that suggests it could be worth just ¥2,508.

    Form Your Own Verdict

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Ono Pharmaceutical?

    If you want to put Ono Pharmaceutical in context, it helps to line it up against other opportunities that match your risk profile and income goals. The Simply Wall St Screener lets you scan the market quickly, then zoom in on companies that fit the way you like to invest.

    • For investors who want income with staying power, review a curated set of established payers through 14 dividend fortresses that may complement Ono Pharmaceutical in a yield focused portfolio.
    • If capital preservation and steadier balance sheets matter most, filter for sturdier businesses using the 21 resilient stocks with low risk scores to see which stocks align with a lower risk approach.
    • To uncover potential opportunities that are not widely followed, broaden your watchlist with the 74 high quality undiscovered gems and see which lesser known companies have fundamentals that stack up.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.